Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

References

• Pancreatic Cancer Action Network: The alarming rise of pancreatic cancer deaths in the U.S.2012 Available from: https://www.pancan.org/reports/report-the-alarming-rise-of-pancreatic-cancer-deaths-in-the-u-s-2/Accessed October 3, 2016
   Google Scholar
• American Cancer SocietyCancer Facts and Figures2016 Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdfAccessed October 3, 2016
   Google Scholar
• RahibLSmithBDAizenbergRRosenzweigABFleshmanJMMatrisianLMProjecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United StatesCancer Res201474112913292124840647
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results Program: SEER stat facts sheets: pancreas cancer Updated 2016. Available from: http://seer.cancer.gov/statfacts/html/pancreas.htmlAccessed October 3, 2016
   Google Scholar
• BurrisHAIIIMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma V22016 https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfAccessed October 3, 2016
   Google Scholar
• ColucciGLabiancaRDi CostanzoFRandomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 studyJ Clin Oncol201028101645165120194854
   PubMed Web of Science ®Google Scholar
• KindlerHLNiedzwieckiDHollisDGemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)J Clin Oncol201028223617362220606091
   PubMed Web of Science ®Google Scholar
• GoncalvesAGilabertMFrancoisEBAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancerAnn Oncol201223112799280522771827
   PubMed Web of Science ®Google Scholar
• CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJ Clin Oncol200927335513551819858379
   PubMed Web of Science ®Google Scholar
• PoplinEFengYBerlinJPhase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupJ Clin Oncol200927233778378519581537
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol200624274441444716983112
   PubMed Web of Science ®Google Scholar
• StathopoulosGPSyrigosKAravantinosGA multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBr J Cancer200695558759216909140
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200725151960196617452677
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• GoldsteinDEl-MaraghiRHHammelPNab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trialJ Natl Cancer Inst20151072dju41325638248
   PubMedGoogle Scholar
• Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• PeixotoRDHoMRenoufDJEligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOXAm J Clin Oncol Epub201541
   PubMed Web of Science ®Google Scholar
• HutchinsLFUngerJMCrowleyJJColtmanCAJrAlbainKSUnder-representation of patients 65 years of age or older in cancer-treatment trialsN Engl J Med1999341272061206710615079
   PubMed Web of Science ®Google Scholar
• PeddiPFLubnerSMcWilliamsRMulti-institutional experience with FOLFIRINOX in pancreatic adenocarcinomaJOP201213549750122964956
   PubMedGoogle Scholar
• AbramsTAMeyerGMoloneyJPatterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC)J Clin Oncol201432suppl 5 abstr 4131
   Google Scholar
• TaberneroJChioreanEGInfanteJRPrognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerOncologist201520214315025582141
   PubMed Web of Science ®Google Scholar
• AttardCLBrownSAlloulKMooreMJCost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancerJ Clin Oncol201230suppl 4 abstr 199
   Web of Science ®Google Scholar
• GhalautPSSenRDixitGRole of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropeniaJ Assoc Physicians India20085694294419322972
   PubMedGoogle Scholar
• KimGPParisiMPatelMReal world hospital costs associated with nab-paclitaxel plus gemcitabine (nab-P+G) and FOLFIRINOX (FFX) as first line (1L) treatment (tx) for metastatic pancreatic adenocarcinoma (MPAC)J Clin Oncol201634suppl abstr e15741
   Google Scholar